{"id":390958,"date":"2017-06-12T00:00:00","date_gmt":"2017-06-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2017-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2017\/"},"modified":"2026-05-06T11:24:24","modified_gmt":"2026-05-06T11:24:24","slug":"unneon0010-2017-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2017-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2017\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck | Unmet Need | US\/EU | 2017"},"content":{"rendered":"<p>Prior to 2016, the therapeutic landscape for recurrent or metastatic squamous cell carcinoma of the head and neck (<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>) had only\u00a0benefited from the introduction of one novel treatment, Erbitux, in 2011. However, after years of dormancy, the immune checkpoint inhibitors, Keytruda and Opdivo, are beginning to transform the recurrent or metastatic <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>\u00a0treatment paradigm.<\/p>\n<p>The understanding of unmet need is crucial for identifying opportunities in <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>\u00a0drug development, particularly because\u00a0not all unmet needs are worth pursuing. We focus on the commercially important recurrent and metastatic population, the setting for which two <abbr title=\"programmed cell death-1\">PD-1<\/abbr> inhibitors Opdivo and Keytruda gained <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval in 2016. We assess how <abbr title=\"programmed cell death-1\">PD-1<\/abbr> inhibitors and other therapies perform on key drug attributes and measure the impact of drug attributes on physicians\u2019 prescribing behavior. We identify potential hidden opportunities and consider which emerging therapies (e.g., durvalumab), if any, may be poised to capitalize. Using conjoint analysis, we determine the trade-offs across key drug attributes (including duration of response and quality of life) and price that surveyed physicians are willing to make when considering the first-line recurrent and metastatic treatment setting; these results\u00a0allow\u00a0us to simulate physician and prescribing likelihood across different <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> target product profiles.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for recurrent or metastatic non-nasopharyngeal <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>?<\/li>\n<li>What attributes are key influencers\u00a0that have\u00a0limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for recurrent or metastatic non-nasopharyngeal <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in recurrent or metastatic non-nasopharyngeal <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to <abbr title=\"United States\">U.S.<\/abbr> and European medical oncologists\u00a0for a hypothetical new recurrent or metastatic non-nasopharyngeal <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, and Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 <abbr title=\"United States\">U.S.<\/abbr> and 31 European medical oncologists,\u00a0fielded in December\u00a02016<\/p>\n<p><strong>Key companies:<\/strong> Merck &#038; Co., Bristol-Myers Squibb, AstraZeneca, Eli Lilly<\/p>\n<p><strong>Key drugs:<\/strong> Erbitux, Keytruda, Opdivo, durvalumab, docetaxel, paclitaxel<\/p>\n","protected":false},"template":"","class_list":["post-390958","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390958\/revisions"}],"predecessor-version":[{"id":576832,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390958\/revisions\/576832"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}